BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

...That changed in March when multiple companies announced venture rounds, including Abbisko Therapeutics Co. Ltd., Asieris Pharmaceuticals Co. Ltd....
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...in multiple Phase II trials to treat solid tumors. Yanyuan Capital leads Asieris’ series C Asieris...
...accuracy of those statements during the COVID-19 crisis. Targets MetAP2 - Methionine aminopeptidase 2 BioCentury Staff APL-1202 Apexigen Inc. Asieris...
BioCentury | Jan 5, 2018
Financial News

Asieris raises series B round

...January. Asieris said the over-booked round should fund operations for about 18 months. This year, Asieris...
...an ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end. Asieris...
...the oral methionine aminopeptidase 2 (MetAP2) enzyme inhibitor from Johns Hopkins University. Asieris Pharmaceuticals Co. Ltd., Taizhou, China Jennie Walters APL-1202 Asieris...
BioCentury | Dec 29, 2017
Financial News

Asieris raises series B round

...month. Asieris said the over-booked round should fund operations for about 18 months. In 2018, Asieris...
...ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end 2018. Asieris...
...exclusive rights to the oral methionine aminopeptidase 2 (MetAP2) enzyme inhibitor from Johns Hopkins University. Jennie Walters APL-1202 Asieris...
Items per page:
1 - 4 of 4
BioCentury | Apr 18, 2020
Finance

Venture funding back on track as China’s investors recalibrate

...That changed in March when multiple companies announced venture rounds, including Abbisko Therapeutics Co. Ltd., Asieris Pharmaceuticals Co. Ltd....
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

...in multiple Phase II trials to treat solid tumors. Yanyuan Capital leads Asieris’ series C Asieris...
...accuracy of those statements during the COVID-19 crisis. Targets MetAP2 - Methionine aminopeptidase 2 BioCentury Staff APL-1202 Apexigen Inc. Asieris...
BioCentury | Jan 5, 2018
Financial News

Asieris raises series B round

...January. Asieris said the over-booked round should fund operations for about 18 months. This year, Asieris...
...an ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end. Asieris...
...the oral methionine aminopeptidase 2 (MetAP2) enzyme inhibitor from Johns Hopkins University. Asieris Pharmaceuticals Co. Ltd., Taizhou, China Jennie Walters APL-1202 Asieris...
BioCentury | Dec 29, 2017
Financial News

Asieris raises series B round

...month. Asieris said the over-booked round should fund operations for about 18 months. In 2018, Asieris...
...ongoing Chinese Phase III trial to treat relapsed NMIBC are expected by year end 2018. Asieris...
...exclusive rights to the oral methionine aminopeptidase 2 (MetAP2) enzyme inhibitor from Johns Hopkins University. Jennie Walters APL-1202 Asieris...
Items per page:
1 - 4 of 4